Newswire
Peptide and metabolic-medicine headlines from established outlets, journals and regulators. Where the story touches a compound we track, we read it against the studies on file; otherwise the headline links straight out. We summarise, we never republish.
Swept 5h ago · 31 outlets
TirzepatideLast 30 days · 47 items
LeadReutersNov 4, 2026
NEWSLETTER: GLP-1 drugs help control prediabetes better than current standard medicine - Reuters
Why it matters
The headline reports that GLP-1 drugs are more effective in controlling prediabetes compared to the current standard medicine.
AI-generated context · not editorial opinion
Yesterday
The Washington PostColumn | Asking Eric: GLP-1 use disrupts friend group - The Washington PostThe story discusses how the use of GLP-1 medications has caused disruptions within a friend group. It likely explores the social dynamics and implications of using these treatments among friends.Nov 4, 2026The GuardianAustralia’s first GLP-1 weight-loss pill has been approved. How does it differ to injections and who will be eligible? - The GuardianAustralia has approved its first GLP-1 weight-loss pill. The article discusses how this pill differs from existing injection forms and outlines the eligibility criteria for potential users.Nov 4, 2026Monday, Nov 2
MedscapeCan Storage Mistakes Ruin a GLP-1 Drug? - MedscapeThe headline raises a question about the potential impact of storage mistakes on a GLP-1 drug. It suggests that improper storage may have negative consequences for the drug's effectiveness or safety. Further details are not provided in the description.Nov 2, 2026MedscapeGLP-1 Therapies Not Linked to Increased Fracture Risk in Three Studies - MedscapeThree studies report that GLP-1 therapies are not associated with an increased risk of fractures.Nov 2, 2026Thursday, Oct 29
ReutersLilly's obesity drug strength fuels record rally, Wall Street optimism - ReutersThe headline reports that Lilly's obesity drug strength has contributed to a record rally and optimism on Wall Street.Oct 29, 2026MedscapeWeight-Loss Surgery Tops Tirzepatide in Diverse Obesity Cohort - MedscapeThe headline reports that weight-loss surgery is more effective than Tirzepatide in a diverse group of individuals with obesity.TirzepatideWednesday, Oct 28
STATPharmalittle: We're reading about 340B battles, new results for a Lilly weight loss drug, and more - STATThe headline indicates that the article discusses various topics, including ongoing disputes related to the 340B drug pricing program, new results concerning a Lilly weight loss drug, and additional related news in the pharmaceutical sector.Oct 28, 2026MedscapePost-GLP-1 Weight Regain Eased by Support Tools - MedscapeThe story reports that support tools may help ease weight regain after the use of GLP-1 receptor agonists.Oct 28, 2026MedscapeHair Loss Associated With GLP-1 RAs Appear Similar by Race - MedscapeThe story reports that hair loss associated with GLP-1 receptor agonists appears to be similar across different racial groups.Oct 28, 2026Tuesday, Oct 27
The Guardian‘I was so sick’: is running a marathon while on a GLP-1 a bad idea? - The GuardianThe story explores the implications of running a marathon while using a GLP-1 medication, raising questions about the potential risks and effects on health during such an intense physical activity. It suggests a discussion around the suitability of combining endurance sports with this type of treatment.Oct 27, 2026MedscapeMost Patients Know About GLP-1 Uses, but Knowledge Gaps Remain - MedscapeThe story reports that most patients are aware of the uses of GLP-1, but there are still gaps in their knowledge regarding this treatment.Oct 27, 2026MedscapeGLP-1 Misinformation Is Straining Primary Care - MedscapeThe headline indicates that misinformation regarding GLP-1 is causing challenges in primary care settings. It suggests that this misinformation may be impacting the way primary care providers manage patient care related to GLP-1. Further details are not provided in the description.Oct 27, 2026Monday, Oct 26
ReutersUS judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk - ReutersOct 26, 2026Friday, Oct 23
ReutersEXCLUSIVE: Dr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit - ReutersDr Reddy's has launched new generic brands of Ozempic, which contains semaglutide, in response to supply issues affecting Obeda.Oct 23, 2026ReutersGLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says - ReutersJ.P. Morgan reports that the growing use of GLP-1 in China, India, and Brazil could lead to a market valued at $22 billion by 2035.Oct 23, 2026Thursday, Oct 22
STATTelehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction - STATThe story reports that telehealth services are advancing beyond FDA approval processes by offering off-label prescriptions of GLP-1 for addiction treatment.Oct 22, 2026Science DailyPeople are taking an unapproved weight-loss drug. AI found something surprising - Science DailyOct 22, 2026Wednesday, Oct 21
The Cureus Journal of Medical ScienceEfficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Adolescents With Obesity: A Retrospective Study - The Cureus Journal of Medical ScienceThe story reports on a retrospective study examining the efficacy and safety of once-weekly subcutaneous Semaglutide in adolescents with obesity.Oct 21, 2026MedscapeGLP-1 Gender Gap: Why Are Men Being Left Out? - MedscapeThe headline suggests that there is a gender disparity in the use or research of GLP-1 therapies, specifically indicating that men may be underrepresented or excluded in some context related to these treatments. The article likely explores the reasons behind this gap.Oct 21, 2026Tuesday, Oct 20
ReutersAs weight-loss drug users turn to dietary supplements, doctors and regulators raise flags - ReutersOct 20, 2026MedscapeCould Retatrutide Break a GLP-1 Weight-Loss Plateau? - MedscapeThe headline suggests that there is a possibility that Retatrutide (LY3437943) could help individuals overcome a weight-loss plateau associated with GLP-1 treatments. The story implies an exploration of Retatrutide's potential effects on weight management. Further details are not provided.Oct 20, 2026Monday, Oct 19
ReutersCherry or tabasco? Perfumers test weight-loss drug users' appetite for food-inspired scents - ReutersOct 19, 2026Mayo Clinic News NetworkGLP-1 drugs linked to lower kidney failure risk in bipolar disorder - Mayo Clinic News NetworkThe headline reports a link between GLP-1 drugs and a lower risk of kidney failure in individuals with bipolar disorder.Oct 19, 2026Friday, Oct 16
The New York TimesThe Difficulty of Diagnosing Anorexia in the GLP-1 Era - The New York TimesThe story discusses the challenges associated with diagnosing anorexia in the context of the use of GLP-1 receptor agonists. It highlights the complexities that arise due to the effects of these medications on appetite and weight.Oct 16, 2026NatureReal-world, digital-first delivery of GLP-1 receptor agonist therapy in women - NatureThe story reports on the real-world and digital-first delivery of GLP-1 receptor agonist therapy specifically in women. It suggests a focus on how this therapy is being implemented and accessed in a practical setting. Further details are not provided in the description.Oct 16, 2026MedscapeMany 'Branded' GLP-1 Users on Compounded Drugs, Photos Show - MedscapeThe headline reports that many users of branded GLP-1 medications are actually using compounded drugs, as indicated by photos.Oct 16, 2026MedscapePatients Taking GLP-1s Face a Double Dose of Stigma - MedscapeThe headline suggests that patients taking GLP-1s experience stigma, potentially indicating that there are negative perceptions or social challenges associated with their use of these medications. The article likely explores the implications of this stigma for patients.Oct 16, 2026ReutersWeight-loss drug developers line up to tap lucrative market as competition heats up - ReutersOct 16, 2026Tuesday, Oct 13
ReutersZealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion - ReutersOct 13, 2026MedscapeMed Op-Ed: Cookies Hook, Bariatric Surgery Endures, Tirzepatide Tempts - MedscapeThe headline suggests a discussion in an op-ed format regarding the addictive nature of cookies, the ongoing relevance of bariatric surgery, and the appeal of Tirzepatide. It implies an exploration of these topics in relation to health and weight management.Oct 13, 2026Monday, Oct 12
MedscapeOral Semaglutide Obesity Rx Tops 100K Monthly in 2 Months - MedscapeThe headline reports that oral Semaglutide prescriptions for obesity have exceeded 100,000 monthly within a two-month period.Oct 12, 2026MedscapeGLP-1 Medications in Teens With Obesity Show Strong Weight Loss but Lack Long-term or Growth Data - MedscapeThe headline reports that GLP-1 medications used in teenagers with obesity demonstrate significant weight loss. However, it also notes a lack of data regarding the long-term effects and growth outcomes associated with these treatments.Oct 12, 2026Wednesday, Oct 7
ReutersZealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trial - ReutersOct 7, 2026ReutersWHO endorses lifestyle changes over GLP-1 drugs in child obesity fight - ReutersThe World Health Organization has endorsed lifestyle changes as a preferred approach over GLP-1 drugs in addressing childhood obesity.Oct 7, 2026Thursday, Oct 1
MedscapeEloraTZP Boosts Weight Loss, A1c Reduction in T2D - MedscapeOct 1, 2026NatureEffects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial - NatureThe headline reports on a randomized placebo-controlled trial investigating the effects of semaglutide on kidney disease in individuals with type 2 diabetes.Oct 1, 2026Wednesday, Sep 30
ReutersRegeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - ReutersA trial reported that Regeneron's weight-loss drug, when combined with Novo's semaglutide, resulted in a reduction of muscle loss by half.Sep 30, 2026ReutersExperimental Lilly combination drug tops Zepbound in weight-loss trial - ReutersSep 30, 2026ReutersWeight-loss drug developers line up to tap lucrative market as competition heats up - ReutersSep 30, 2026Tuesday, Sep 29
NatureOral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial - NatureThe headline reports on a randomized, double-blind, placebo-controlled trial investigating the oral small-molecule GLP-1 receptor agonist safiglipron in individuals with early type 2 diabetes.Sep 29, 2026MedscapeNavigating GLP-1 Switches: A Guide for Primary Care - MedscapeThe headline suggests that the article provides guidance for primary care providers on managing switches between GLP-1 receptor agonists. It likely addresses considerations and strategies for effectively navigating these transitions in patient care.Sep 29, 2026Showing 48 of 47 filed in the last 30 days
r/Semaglutide · Nov 3, 2026SERIOUS WARNING!!r/Semaglutide · Nov 2, 2026The journey this farr/Peptides · Nov 2, 2026Apple going scorched earth on peptide calculator apps?r/Semaglutide · Nov 1, 20262 years, 96 shots and 125lbs later.r/Semaglutide · Oct 31, 2026Same costume, 1 year apartr/Mounjaro · Oct 31, 2026Muscle Loss and GLP’s
Educational use only — not medical advice. Headlines are summarised, not endorsed, and a story appearing here is not a claim that its findings are correct.